WWM
NBIX icon

Whalen Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Whalen Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$851K Buy
6,462
+1,337
+26% +$177K 0.46% 57
2025
Q4 		$727K Buy
5,125
+663
+15% +$96.1K 0.39% 68
2025
Q3 		$626K Buy
4,462
+833
+23% +$113K 0.37% 65
2025
Q2 		$456K Buy
3,629
+235
+7% +$26.9K 0.29% 103
2025
Q1 		$375K Buy
3,394
+1,461
+76% +$185K 0.25% 92
2024
Q4 		$264K Buy
+1,933
New +$239K 0.18% 107

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Whalen Wealth Management's NBIX Position: Q1 2026 in Review

Whalen Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 26% in Q1 2026, buying an estimated $177K and bringing the position to 6,462 shares worth $851K. The position accounts for 0.46% of the portfolio, ranked #57.

Whalen Wealth Management first reported a position in NBIX in Q4 2024 and has held it in 6 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Whalen Wealth Management held 6,462 shares of Neurocrine Biosciences worth $851K as of Q1 2026.
  • Whalen Wealth Management bought 1,337 Neurocrine Biosciences shares in Q1 2026, an estimated $177K.
  • Neurocrine Biosciences made up 0.46% of Whalen Wealth Management's portfolio in Q1 2026, its #57 holding.
  • Whalen Wealth Management first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 6 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Whalen Wealth Management's 13F filing for Q1 2026, filed 13 Apr 2026.